Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.

Chikata T, Paes W, Akahoshi T, Partridge T, Murakoshi H, Gatanaga H, Ternette N, Oka S, Borrow P, Takiguchi M.

J Virol. 2019 Aug 13;93(17). pii: e00634-19. doi: 10.1128/JVI.00634-19. Print 2019 Sep 1.

2.

Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.

Zou C, Murakoshi H, Kuse N, Akahoshi T, Chikata T, Gatanaga H, Oka S, Hanke T, Takiguchi M.

J Virol. 2019 Mar 21;93(7). pii: e02142-18. doi: 10.1128/JVI.02142-18. Print 2019 Apr 1.

3.

Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication.

Murakoshi H, Kuse N, Akahoshi T, Zhang Y, Chikata T, Borghan MA, Gatanaga H, Oka S, Sakai K, Takiguchi M.

J Virol. 2018 Dec 10;93(1). pii: e01480-18. doi: 10.1128/JVI.01480-18. Print 2019 Jan 1.

4.

Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control.

Murakoshi H, Koyanagi M, Akahoshi T, Chikata T, Kuse N, Gatanaga H, Rowland-Jones SL, Oka S, Takiguchi M.

EBioMedicine. 2018 Oct;36:103-112. doi: 10.1016/j.ebiom.2018.09.022. Epub 2018 Sep 22.

5.

CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication.

Murakoshi H, Zou C, Kuse N, Akahoshi T, Chikata T, Gatanaga H, Oka S, Hanke T, Takiguchi M.

Retrovirology. 2018 Jul 3;15(1):46. doi: 10.1186/s12977-018-0429-y.

6.

HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E.

Chikata T, Tran GV, Murakoshi H, Akahoshi T, Qi Y, Naranbhai V, Kuse N, Tamura Y, Koyanagi M, Sakai S, Nguyen DH, Nguyen DT, Nguyen HT, Nguyen TV, Oka S, Martin MP, Carrington M, Sakai K, Nguyen KV, Takiguchi M.

J Virol. 2018 Feb 12;92(5). pii: e01749-17. doi: 10.1128/JVI.01749-17. Print 2018 Mar 1.

7.

Control of HIV-1 by an HLA-B*52:01-C*12:02 Protective Haplotype.

Chikata T, Murakoshi H, Koyanagi M, Honda K, Gatanaga H, Oka S, Takiguchi M.

J Infect Dis. 2017 Dec 12;216(11):1415-1424. doi: 10.1093/infdis/jix483.

PMID:
28968792
8.

Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection.

Gatanaga H, Brumme ZL, Adland E, Reyes-Terán G, Avila-Rios S, Mejía-Villatoro CR, Hayashida T, Chikata T, Van Tran G, Van Nguyen K, Meza RI, Palou EY, Valenzuela-Ponce H, Pascale JM, Porras-Cortés G, Manzanero M, Lee GQ, Martin JN, Carrington MN, John M, Mallal S, Poon AFY, Goulder P, Takiguchi M, Oka S; International HIV Adaptation Collaborative.

AIDS. 2017 Sep 10;31(14):1935-1943. doi: 10.1097/QAD.0000000000001575.

PMID:
28650381
9.

Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses.

Murakoshi H, Koyanagi M, Chikata T, Rahman MA, Kuse N, Sakai K, Gatanaga H, Oka S, Takiguchi M.

J Virol. 2017 Jan 31;91(4). pii: e02082-16. doi: 10.1128/JVI.02082-16. Print 2017 Feb 15.

10.

HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-C12:02/C14:03.

Lin Z, Kuroki K, Kuse N, Sun X, Akahoshi T, Qi Y, Chikata T, Naruto T, Koyanagi M, Murakoshi H, Gatanaga H, Oka S, Carrington M, Maenaka K, Takiguchi M.

Cell Rep. 2016 Nov 22;17(9):2210-2220. doi: 10.1016/j.celrep.2016.10.075.

11.

Erratum to: Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.

Sakai K, Chikata T, Brumme ZL, Brumme CJ, Gatanaga H, Oka S, Takiguchi M.

Retrovirology. 2015 Nov 30;12:100. doi: 10.1186/s12977-015-0227-8. No abstract available.

12.

A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection.

Van Tran G, Chikata T, Carlson JM, Murakoshi H, Nguyen DH, Tamura Y, Akahoshi T, Kuse N, Sakai K, Sakai S, Cobarrubias K, Oka S, Brumme ZL, Van Nguyen K, Takiguchi M; NHTD Treatment-Naive Cohort Study Group.

AIDS. 2016 Mar 13;30(5):681-9. doi: 10.1097/QAD.0000000000000969.

PMID:
26595539
13.
14.

Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.

Kuse N, Rahman MA, Murakoshi H, Tran GV, Chikata T, Koyanagi M, Nguyen KV, Gatanaga H, Oka S, Takiguchi M.

J Virol. 2015 Jul;89(14):7363-72. doi: 10.1128/JVI.00974-15. Epub 2015 May 13.

15.

Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes.

Murakoshi H, Akahoshi T, Koyanagi M, Chikata T, Naruto T, Maruyama R, Tamura Y, Ishizuka N, Gatanaga H, Oka S, Takiguchi M.

J Virol. 2015 May;89(10):5330-9. doi: 10.1128/JVI.00020-15. Epub 2015 Mar 4.

16.

Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition.

Rahman MA, Kuse N, Murakoshi H, Chikata T, Gatanaga H, Oka S, Takiguchi M.

Microbes Infect. 2014 May;16(5):434-8. doi: 10.1016/j.micinf.2014.03.003. Epub 2014 Mar 20.

PMID:
24657622
17.

Host-specific adaptation of HIV-1 subtype B in the Japanese population.

Chikata T, Carlson JM, Tamura Y, Borghan MA, Naruto T, Hashimoto M, Murakoshi H, Le AQ, Mallal S, John M, Gatanaga H, Oka S, Brumme ZL, Takiguchi M.

J Virol. 2014 May;88(9):4764-75. doi: 10.1128/JVI.00147-14. Epub 2014 Feb 12.

18.

Identification of cross-clade CTL epitopes in HIV-1 clade A/E-infected individuals by using the clade B overlapping peptides.

Watanabe K, Murakoshi H, Tamura Y, Koyanagi M, Chikata T, Gatanaga H, Oka S, Takiguchi M.

Microbes Infect. 2013 Nov;15(13):874-86. doi: 10.1016/j.micinf.2013.08.002. Epub 2013 Aug 19.

PMID:
23968885
19.

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.

Gatanaga H, Murakoshi H, Hachiya A, Hayashida T, Chikata T, Ode H, Tsuchiya K, Sugiura W, Takiguchi M, Oka S.

Clin Infect Dis. 2013 Oct;57(7):1051-5. doi: 10.1093/cid/cit430. Epub 2013 Jun 23.

PMID:
23797286
20.

A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells.

Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, Chikata T, Kuse N, Fastenackels S, Gostick E, Bridgeman JS, Venturi V, Arkoub ZA, Agut H, van Bockel DJ, Almeida JR, Douek DC, Meyer L, Venet A, Takiguchi M, Rossjohn J, Price DA, Appay V.

Immunity. 2013 Mar 21;38(3):425-36. doi: 10.1016/j.immuni.2012.11.021.

21.

Distinct HIV-1 escape patterns selected by cytotoxic T cells with identical epitope specificity.

Yagita Y, Kuse N, Kuroki K, Gatanaga H, Carlson JM, Chikata T, Brumme ZL, Murakoshi H, Akahoshi T, Pfeifer N, Mallal S, John M, Ose T, Matsubara H, Kanda R, Fukunaga Y, Honda K, Kawashima Y, Ariumi Y, Oka S, Maenaka K, Takiguchi M.

J Virol. 2013 Feb;87(4):2253-63. doi: 10.1128/JVI.02572-12. Epub 2012 Dec 12.

22.

Unbiased analysis of TCRα/β chains at the single-cell level in human CD8+ T-cell subsets.

Sun X, Saito M, Sato Y, Chikata T, Naruto T, Ozawa T, Kobayashi E, Kishi H, Muraguchi A, Takiguchi M.

PLoS One. 2012;7(7):e40386. doi: 10.1371/journal.pone.0040386. Epub 2012 Jul 6.

23.

Selection and accumulation of an HIV-1 escape mutant by three types of HIV-1-specific cytotoxic T lymphocytes recognizing wild-type and/or escape mutant epitopes.

Akahoshi T, Chikata T, Tamura Y, Gatanaga H, Oka S, Takiguchi M.

J Virol. 2012 Feb;86(4):1971-81. doi: 10.1128/JVI.06470-11. Epub 2011 Dec 7.

24.

Selection of HLA-B57-associated Gag A146P mutant by HLA-B∗48:01-restricted Gag140-147-specific CTLs in chronically HIV-1-infected Japanese.

Naruto T, Murakoshi H, Chikata T, Koyanagi M, Kawashima Y, Gatanaga H, Oka S, Takiguchi M.

Microbes Infect. 2011 Aug;13(8-9):766-70. doi: 10.1016/j.micinf.2011.03.009. Epub 2011 Apr 5.

PMID:
21473930
25.

Selection of escape mutant by HLA-C-restricted HIV-1 Pol-specific cytotoxic T lymphocytes carrying strong ability to suppress HIV-1 replication.

Honda K, Zheng N, Murakoshi H, Hashimoto M, Sakai K, Borghan MA, Chikata T, Koyanagi M, Tamura Y, Gatanaga H, Oka S, Takiguchi M.

Eur J Immunol. 2011 Jan;41(1):97-106. doi: 10.1002/eji.201040841. Epub 2010 Dec 3.

26.

Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses.

Koizumi H, Hashimoto M, Fujiwara M, Murakoshi H, Chikata T, Borghan MA, Hachiya A, Kawashima Y, Takata H, Ueno T, Oka S, Takiguchi M.

J Virol. 2010 Jun;84(11):5508-19. doi: 10.1128/JVI.02483-09. Epub 2010 Mar 24.

Supplemental Content

Loading ...
Support Center